ylb113

YLB113 is a **biosimilar of etanercept**, a recombinant fusion protein that acts as a **tumor necrosis factor (TNF) inhibitor**. YLB113 is produced using recombinant DNA technology in Chinese Hamster ovary cells[7][1]. It is designed to closely match Enbrel (the original etanercept) in terms of structure, function, clinical efficacy, and safety, and has demonstrated bioequivalence in pharmacokinetic and efficacy studies in patients with rheumatoid arthritis[5][2]. YLB113 is primarily developed for the treatment of **rheumatoid arthritis** and **juvenile idiopathic arthritis**, and is marketed under the brand name Nepexto in some regions[9][7]. Clinical studies have shown YLB113 to have a comparable safety and immunogenicity profile to Enbrel, but with a lower incidence of injection-site reactions[4][1]. YLB113 is delivered as a solution for subcutaneous injection, including in pre-filled syringe and injection pen formats[10][3].

Brand names

Nepexto

Other names

etanercept biosimilar ylb113